Abstract:Significance Identification of cancer cells in the pleural effusions of lung cancer patients is an important clinical diagnosis to verify the malignant pleural involvement. Elevated glucose uptake is a hallmark of cancer cells and has been used in positron-emission tomography to detect malignant tumors in vivo. We hypothesize that cells with enhanced glucose uptake and without expression of leukocyte markers in pleural effusion or peripheral blood samples are highly likely to be malignant cells that can be confirmed via single-cell sequencing. To this end, a high-throughput metabolic-based assay is developed for rapid detection of rare metabolically active tumor cells in pleural effusion, enabling sensitive diagnosis of malignant pleural effusion in the clinic that is associated with metastatic malignancies. Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies. Accurate detection of tumor cells in pleural fluid is crucial because the presence of MPE denotes an advanced stage of disease and directs a switch in clinical managements. Cytology, as a traditional diagnostic tool, has limited sensitivity especially when tumor cells are not abundant, and may be confounded by reactive mesothelial cells in the pleural fluid. We describe a highly sensitive approach for rapid detection of metabolically active tumor cells in MPE via exploiting the altered glucose metabolism of tumor cells relative to benign cells. Metabolically active tumor cells with high glucose uptake, as evaluated by a fluorescent glucose analog (2-NBDG), are identified by high-throughput fluorescence screening within a chip containing 200,000 addressable microwells and collected for malignancy confirmation via single-cell sequencing. We demonstrate the utility of this approach through analyzing MPE from a cohort of lung cancer patients. Most candidate tumor cells identified are confirmed to harbor the same driver oncogenes as their primary lesions. In some patients, emergence of secondary mutations that mediate acquired resistance to ongoing targeted therapies is also detected before resistance is manifested in the clinical imaging. The detection scheme can be extended to analyze peripheral blood samples. Our approach may serve as a valuable complement to cytology in MPE diagnosis, helping identify the driver oncogenes and resistance-leading mutations for targeted therapies.

Bioluminescent Assays for Glucose and Glutamine Metabolism: High-Throughput Screening for Changes in Extracellular and Intracellular Metabolites

A Novel Micro-Groove Impedance Sensor for 3D Cell Viability Monitoring and High-Throughput Drug Screening

3D Microgroove Electrical Impedance Sensing to Examine 3D Cell Cultures for Antineoplastic Drug Assessment

Rapid analysis of glycolytic and oxidative substrate flux of cancer cells in a microplate

Abstract 441: Bioluminescent dehydrogenase assays: A novel approach for metabolic profiling and inhibitor screening in cancer biology

Bioluminescent Assay for the Quantification of Cellular Glycogen Levels

Rapid Probing of Glucose Influx into Cancer Cell Metabolism: Using Adjuvant and a pH-Dependent Collection of Central Metabolites to Improve In-Cell D-DNP NMR

A Bioluminescent Assay for Quantification of Cellular Glycogen Levels

A One-Step Extraction and Luminescence Assay for Quantifying Glucose and ATP Levels in Cultured HepG2 Cells

Engineering the Signal Resolution of a Paper-Based Cell-Free Glutamine Biosensor with Genetic Engineering, Metabolic Engineering, and Process Optimization

Multiplexed Single-Cell Measurements of FDG Uptake and Lactate Release Using Droplet Microfluidics

High-throughput Screening of Rare Metabolically Active Tumor Cells in Pleural Effusion and Peripheral Blood of Lung Cancer Patients

Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.

P2.01-001 Enrichment-Free, Rapid Metabolic Assay for Detection of Tumor Cells in Pleural Effusion and Pheripheral Blood: Topic: Analysis of Body Fluids in Cancer

Novel fluorescent technology platform for high throughput cytotoxicity and proliferation assays

Lymphoma and Leukemia Cell Vulnerabilities and Resistance Identified by Compound Library Screens

Fast Analysis of Intracellular Glucose at Single Cells using Electrochemiluminescence Imaging.

A Screenable In Vivo Assay for Mitochondrial Modulators Using Transgenic Bioluminescent Caenorhabditis elegans

Surface Immobilization of Redox‐Labile Fluorescent Probes: Enabling Single‐Cell Co‐Profiling of Aerobic Glycolysis and Oncogenic Protein Signaling Activities

A high-throughput multiparameter screen for accelerated development and optimization of soluble genetically encoded fluorescent biosensors

Development and Validation of a Rapid, Robust and Sensitive UPLC-QQQ-MS/MS Method for Simultaneous Quantification of GSH Metabolism in Lung Cancer Cells